Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (DFPH) EBIT Margin (2021 - 2025)

Historic EBIT Margin for Oncology Institute (DFPH) over the last 5 years, with Q3 2025 value amounting to 5.9%.

  • Oncology Institute's EBIT Margin rose 79700.0% to 5.9% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.92%, marking a year-over-year increase of 78400.0%. This contributed to the annual value of 15.28% for FY2024, which is 84700.0% up from last year.
  • Oncology Institute's EBIT Margin amounted to 5.9% in Q3 2025, which was up 79700.0% from 9.36% recorded in Q2 2025.
  • Oncology Institute's EBIT Margin's 5-year high stood at 2.24% during Q2 2021, with a 5-year trough of 78.07% in Q4 2021.
  • Moreover, its 5-year median value for EBIT Margin was 16.97% (2023), whereas its average is 21.07%.
  • Over the last 5 years, Oncology Institute's EBIT Margin had its largest YoY gain of 429500bps in 2022, and its largest YoY loss of -298800bps in 2022.
  • Over the past 5 years, Oncology Institute's EBIT Margin (Quarter) stood at 78.07% in 2021, then surged by 55bps to 35.11% in 2022, then soared by 49bps to 17.82% in 2023, then skyrocketed by 33bps to 11.9% in 2024, then skyrocketed by 50bps to 5.9% in 2025.
  • Its EBIT Margin was 5.9% in Q3 2025, compared to 9.36% in Q2 2025 and 9.49% in Q1 2025.